DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADB269116
Title:
Differential Activation of p53 Target Genes in Breast Cancer
Descriptive Note:
Annual summary rept. 1 May 2000-1 May 2001
Corporate Author:
MOUNT SINAI SCHOOL OF MEDICINE NEW YORK
Report Date:
2001-06-01
Pagination or Media Count:
45.0
Abstract:
A significant percentage of breast tumors are resistant to apoptotic stimuli. This resistance has been correlated with decreased expression of the proapoptotic protein bax. A major regulator of bax expression is the tumor suppressor p53. Unlike other well characterized p53 response elements, like the p21-5 element, which consist of two consensus p53 half-sites, the response element of the human bax promoter consists of three half-sites that cooperate in mediating p53-dependent transactivation. Within this unique response element are six GC-rich base pairs that mediate an interaction with Sp1 both in vitro and in cells. These bases were found to be required for p53-dependent activation, and mutations that inhibited Sp1 binding also blocked the ability of p53 to activate transcription through this element, suggesting a model in which p53 requires the cooperation of Sp1 or a Sp1-like factor to mediate transcriptional activation of the human bax promoter. In addition, I recently identified a novel p53 response element conserved in the first intron of both the human and the murine box genes. This element is required for the p53-dependent transcriptional activation of both the human and murine bax genes, demonstrating that box is a direct and evolutionarily conserved transcriptional target of p53.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE